000139681412/312025Q1FALSEP0D0.0252752.973.0139324.986xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:purepcrx:productpcrx:customerpcrx:leasepcrx:daypcrx:trading_daypcrx:wholesalerpcrx:offeringPeriodpcrx:segment00013968142025-01-012025-03-310001396814dei:FormerAddressMember2025-01-012025-03-3100013968142025-05-0700013968142025-03-3100013968142024-12-310001396814us-gaap:ProductMember2025-01-012025-03-310001396814us-gaap:ProductMember2024-01-012024-03-310001396814us-gaap:RoyaltyMember2025-01-012025-03-310001396814us-gaap:RoyaltyMember2024-01-012024-03-3100013968142024-01-012024-03-310001396814us-gaap:CommonStockMember2024-12-310001396814us-gaap:TreasuryStockCommonMember2024-12-310001396814us-gaap:AdditionalPaidInCapitalMember2024-12-310001396814us-gaap:RetainedEarningsMember2024-12-310001396814us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001396814us-gaap:CommonStockMember2025-01-012025-03-310001396814us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001396814us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001396814us-gaap:RetainedEarningsMember2025-01-012025-03-310001396814us-gaap:CommonStockMember2025-03-310001396814us-gaap:TreasuryStockCommonMember2025-03-310001396814us-gaap:AdditionalPaidInCapitalMember2025-03-310001396814us-gaap:RetainedEarningsMember2025-03-310001396814us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001396814us-gaap:CommonStockMember2023-12-310001396814us-gaap:AdditionalPaidInCapitalMember2023-12-310001396814us-gaap:RetainedEarningsMember2023-12-310001396814us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-3100013968142023-12-310001396814us-gaap:CommonStockMember2024-01-012024-03-310001396814us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001396814us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001396814us-gaap:RetainedEarningsMember2024-01-012024-03-310001396814us-gaap:CommonStockMember2024-03-310001396814us-gaap:AdditionalPaidInCapitalMember2024-03-310001396814us-gaap:RetainedEarningsMember2024-03-310001396814us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-3100013968142024-03-310001396814pcrx:TermLoanAFacilityMember2025-01-012025-03-310001396814pcrx:TermLoanAFacilityMember2024-01-012024-03-310001396814pcrx:GQBioTherapeuticsGmbHMember2025-02-280001396814us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-03-310001396814us-gaap:CustomerConcentrationRiskMember2025-01-012025-03-310001396814pcrx:LargestCustomerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-03-310001396814pcrx:LargestCustomerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310001396814pcrx:SecondLargestCustomerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-03-310001396814pcrx:SecondLargestCustomerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310001396814pcrx:ThirdLargestCustomerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-03-310001396814pcrx:ThirdLargestCustomerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310001396814pcrx:ThreeLargestCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-03-310001396814pcrx:ThreeLargestCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310001396814pcrx:GQBioAcquisitionMemberpcrx:GQBioAcquisitionMember2025-02-250001396814pcrx:GQBioAcquisitionMember2025-02-252025-02-250001396814pcrx:GQBioAcquisitionMember2025-02-250001396814pcrx:GQBioAcquisitionMember2025-01-012025-03-310001396814pcrx:GQBioAcquisitionMemberus-gaap:InProcessResearchAndDevelopmentMemberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMember2025-02-250001396814srt:MinimumMember2025-01-012025-03-310001396814srt:MaximumMember2025-01-012025-03-310001396814pcrx:EXPARELMember2025-01-012025-03-310001396814pcrx:EXPARELMember2024-01-012024-03-310001396814pcrx:ZILRETTAMember2025-01-012025-03-310001396814pcrx:ZILRETTAMember2024-01-012024-03-310001396814pcrx:IoveraMember2025-01-012025-03-310001396814pcrx:IoveraMember2024-01-012024-03-310001396814pcrx:BupivacaineLiposomeInjectableSuspensionMember2025-01-012025-03-310001396814pcrx:BupivacaineLiposomeInjectableSuspensionMember2024-01-012024-03-310001396814us-gaap:MachineryAndEquipmentMember2025-03-310001396814us-gaap:MachineryAndEquipmentMember2024-12-310001396814us-gaap:LeaseholdImprovementsMember2025-03-310001396814us-gaap:LeaseholdImprovementsMember2024-12-310001396814pcrx:ComputerEquipmentAndSoftwareMember2025-03-310001396814pcrx:ComputerEquipmentAndSoftwareMember2024-12-310001396814us-gaap:FurnitureAndFixturesMember2025-03-310001396814us-gaap:FurnitureAndFixturesMember2024-12-310001396814us-gaap:ConstructionInProgressMember2025-03-310001396814us-gaap:ConstructionInProgressMember2024-12-310001396814us-gaap:ConstructionInProgressMember2025-01-012025-03-310001396814pcrx:LeaseholdImprovementsAndMachineryAndEquipmentMember2025-01-012025-03-310001396814us-gaap:NonUsMemberus-gaap:LeaseholdImprovementsMember2025-03-310001396814us-gaap:NonUsMemberus-gaap:LeaseholdImprovementsMember2024-12-310001396814pcrx:GermanyAndBelgiumMemberpcrx:GQBioAcquisitionMember2025-03-3100013968142024-01-012024-12-310001396814us-gaap:DevelopedTechnologyRightsMember2025-03-310001396814us-gaap:DevelopedTechnologyRightsMember2025-01-012025-03-310001396814us-gaap:CustomerRelationshipsMember2025-03-310001396814us-gaap:CustomerRelationshipsMember2025-01-012025-03-310001396814us-gaap:InProcessResearchAndDevelopmentMember2025-03-310001396814us-gaap:InProcessResearchAndDevelopmentMember2025-01-012025-03-310001396814us-gaap:DevelopedTechnologyRightsMember2024-12-310001396814us-gaap:DevelopedTechnologyRightsMember2024-01-012024-12-310001396814us-gaap:CustomerRelationshipsMember2024-12-310001396814us-gaap:CustomerRelationshipsMember2024-01-012024-12-310001396814us-gaap:InProcessResearchAndDevelopmentMember2024-12-310001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:SecuredDebtMember2025-03-310001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:SecuredDebtMember2024-12-310001396814pcrx:ConvertibleSeniorNotesDue2029Memberus-gaap:UnsecuredDebtMember2025-03-310001396814pcrx:ConvertibleSeniorNotesDue2029Memberus-gaap:UnsecuredDebtMember2024-12-310001396814pcrx:ConvertibleSeniorNotesDue2025Memberus-gaap:UnsecuredDebtMember2025-03-310001396814pcrx:ConvertibleSeniorNotesDue2025Memberus-gaap:UnsecuredDebtMember2024-12-310001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:SecuredDebtMember2023-03-310001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:SecuredDebtMember2023-03-312023-03-310001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:SecuredDebtMember2023-06-302023-06-300001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:SecuredDebtMember2025-03-312025-03-310001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:SecuredDebtMembersrt:ScenarioForecastMember2028-03-310001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:SecuredDebtMember2025-01-012025-03-310001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:BaseRateMembersrt:MinimumMember2025-03-310001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:BaseRateMembersrt:MaximumMember2025-03-310001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:SecuredOvernightFinancingRateSofrMembersrt:MinimumMember2025-03-310001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:SecuredOvernightFinancingRateSofrMembersrt:MaximumMember2025-03-310001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:SecuredDebtMember2024-01-012024-12-310001396814pcrx:TermLoanAFacilityDueMarch2028Member2025-03-310001396814pcrx:ConvertibleSeniorNotesDue2029Memberus-gaap:UnsecuredDebtMember2024-05-310001396814pcrx:ConvertibleSeniorNotesDue2029Memberus-gaap:UnsecuredDebtMember2024-05-012024-05-3100013968142024-05-090001396814pcrx:ConvertibleSeniorNotesDue2029Memberus-gaap:UnsecuredDebtMemberpcrx:DebtConversionTermsOneMember2025-03-310001396814pcrx:ConvertibleSeniorNotesDue2029Memberus-gaap:UnsecuredDebtMemberpcrx:DebtConversionTermsOneMember2025-01-012025-03-310001396814pcrx:ConvertibleSeniorNotesDue2029Memberus-gaap:UnsecuredDebtMemberpcrx:DebtConversionTermsTwoMember2025-01-012025-03-310001396814pcrx:ConvertibleSeniorNotesDue2029Memberus-gaap:UnsecuredDebtMemberpcrx:DebtConversionTermsThreeMember2025-03-310001396814pcrx:ConvertibleSeniorNotesDue2029Memberus-gaap:UnsecuredDebtMemberpcrx:DebtConversionTermsThreeMember2025-01-012025-03-310001396814pcrx:ConvertibleSeniorNotesDue2029Memberpcrx:CappedCallMemberus-gaap:ConvertibleDebtMember2024-05-090001396814us-gaap:AdditionalPaidInCapitalMember2024-05-092024-05-090001396814pcrx:ConvertibleSeniorNotesDue2025Memberus-gaap:UnsecuredDebtMember2020-07-310001396814pcrx:ConvertibleSeniorNotesDue2025Memberus-gaap:UnsecuredDebtMember2024-05-310001396814pcrx:ConvertibleSeniorNotesDue2025Memberus-gaap:UnsecuredDebtMember2024-05-012024-05-310001396814pcrx:ConvertibleSeniorNotesDue2025Memberus-gaap:UnsecuredDebtMemberpcrx:DebtConversionTermsBusinessDayImmediatelyPrecedingFebruary32020Member2025-01-012025-03-310001396814pcrx:ConvertibleSeniorNotesDue2025Memberus-gaap:UnsecuredDebtMember2025-01-012025-03-310001396814pcrx:ConvertibleSeniorNotesDue2025Memberus-gaap:UnsecuredDebtMember2020-07-012020-07-310001396814pcrx:ConvertibleSeniorNotesDue2025Memberpcrx:DebtRedemptionTermsOnOrAfterAugust12023Member2023-08-010001396814pcrx:ConvertibleSeniorNotesDue2025Memberpcrx:DebtRedemptionTermsOnOrAfterAugust12023Member2023-08-012023-08-010001396814pcrx:ConvertibleSeniorNotesDue2024Memberpcrx:FlexionTherapeuticsIncMemberus-gaap:UnsecuredDebtMember2017-05-310001396814pcrx:ConvertibleSeniorNotesDue2024Memberus-gaap:UnsecuredDebtMember2022-01-070001396814pcrx:ConvertibleSeniorNotesDue2024Memberus-gaap:UnsecuredDebtMember2024-05-012024-05-010001396814us-gaap:CarryingReportedAmountFairValueDisclosureMember2025-03-310001396814us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2025-03-310001396814us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2025-03-310001396814us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2025-03-310001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SecuredDebtMember2025-03-310001396814us-gaap:FairValueInputsLevel1Memberpcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SecuredDebtMember2025-03-310001396814us-gaap:FairValueInputsLevel2Memberpcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SecuredDebtMember2025-03-310001396814us-gaap:FairValueInputsLevel3Memberpcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SecuredDebtMember2025-03-310001396814pcrx:ConvertibleSeniorNotesDue2029Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:UnsecuredDebtMember2025-03-310001396814us-gaap:FairValueInputsLevel1Memberpcrx:ConvertibleSeniorNotesDue2029Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:UnsecuredDebtMember2025-03-310001396814us-gaap:FairValueInputsLevel2Memberpcrx:ConvertibleSeniorNotesDue2029Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:UnsecuredDebtMember2025-03-310001396814us-gaap:FairValueInputsLevel3Memberpcrx:ConvertibleSeniorNotesDue2029Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:UnsecuredDebtMember2025-03-310001396814pcrx:ConvertibleSeniorNotesDue2025Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:UnsecuredDebtMember2025-03-310001396814us-gaap:FairValueInputsLevel1Memberpcrx:ConvertibleSeniorNotesDue2025Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:UnsecuredDebtMember2025-03-310001396814us-gaap:FairValueInputsLevel2Memberpcrx:ConvertibleSeniorNotesDue2025Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:UnsecuredDebtMember2025-03-310001396814us-gaap:FairValueInputsLevel3Memberpcrx:ConvertibleSeniorNotesDue2025Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:UnsecuredDebtMember2025-03-310001396814pcrx:ConvertibleSeniorNotesDue2025Member2025-01-012025-03-310001396814us-gaap:EquitySecuritiesMember2023-12-310001396814pcrx:ConvertibleNotesReceivableMember2023-12-310001396814us-gaap:EquitySecuritiesMember2024-01-012024-12-310001396814pcrx:ConvertibleNotesReceivableMember2024-01-012024-12-310001396814us-gaap:EquitySecuritiesMember2024-12-310001396814pcrx:ConvertibleNotesReceivableMember2024-12-310001396814us-gaap:EquitySecuritiesMember2025-01-012025-03-310001396814pcrx:ConvertibleNotesReceivableMember2025-01-012025-03-310001396814us-gaap:EquitySecuritiesMember2025-03-310001396814pcrx:ConvertibleNotesReceivableMember2025-03-310001396814pcrx:FlexionAndMyoScienceAcquisitionMember2025-03-310001396814pcrx:FlexionAndMyoScienceAcquisitionMember2024-12-310001396814pcrx:FlexionMember2021-11-300001396814pcrx:FlexionMember2022-08-310001396814pcrx:FlexionMember2021-11-012021-11-300001396814pcrx:FlexionMember2025-01-012025-03-310001396814pcrx:FlexionMember2024-01-012024-03-310001396814pcrx:FlexionMembersrt:WeightedAverageMemberpcrx:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMember2025-03-310001396814pcrx:FlexionMembersrt:MinimumMemberpcrx:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMember2025-03-310001396814pcrx:FlexionMembersrt:MaximumMemberpcrx:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMember2025-03-310001396814pcrx:FlexionMembersrt:MinimumMemberpcrx:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Memberpcrx:MeasurementInputExpectedMilestonePaymentMember2025-03-310001396814pcrx:ContingentConsiderationMember2023-12-310001396814pcrx:ContingentConsiderationMember2024-01-012024-12-310001396814pcrx:ContingentConsiderationMember2024-12-310001396814pcrx:ContingentConsiderationMember2025-01-012025-03-310001396814pcrx:ContingentConsiderationMember2025-03-310001396814us-gaap:ShortTermInvestmentsMemberus-gaap:AssetBackedSecuritiesMember2025-03-310001396814us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:AssetBackedSecuritiesMember2025-03-310001396814us-gaap:ShortTermInvestmentsMemberus-gaap:CommercialPaperMember2025-03-310001396814us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:CommercialPaperMember2025-03-310001396814us-gaap:ShortTermInvestmentsMemberus-gaap:CorporateBondSecuritiesMember2025-03-310001396814us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:CorporateBondSecuritiesMember2025-03-310001396814us-gaap:ShortTermInvestmentsMemberpcrx:YankeeBondMember2025-03-310001396814us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberpcrx:YankeeBondMember2025-03-310001396814us-gaap:FairValueInputsLevel2Member2025-03-310001396814us-gaap:ShortTermInvestmentsMemberus-gaap:AssetBackedSecuritiesMember2024-12-310001396814us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:AssetBackedSecuritiesMember2024-12-310001396814us-gaap:ShortTermInvestmentsMemberus-gaap:CommercialPaperMember2024-12-310001396814us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:CommercialPaperMember2024-12-310001396814us-gaap:ShortTermInvestmentsMemberus-gaap:CorporateBondSecuritiesMember2024-12-310001396814us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:CorporateBondSecuritiesMember2024-12-310001396814us-gaap:ShortTermInvestmentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-12-310001396814us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-12-310001396814us-gaap:ShortTermInvestmentsMemberpcrx:YankeeBondMember2024-12-310001396814us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberpcrx:YankeeBondMember2024-12-310001396814us-gaap:FairValueInputsLevel2Member2024-12-310001396814pcrx:MajorCustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2025-01-012025-03-310001396814pcrx:MajorCustomerTwoMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2025-01-012025-03-310001396814pcrx:MajorCustomerThreeMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2025-01-012025-03-310001396814pcrx:MajorCustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-12-310001396814pcrx:MajorCustomerTwoMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-12-310001396814pcrx:MajorCustomerThreeMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-12-310001396814pcrx:IoveraMember2025-03-310001396814pcrx:IoveraMember2024-12-310001396814us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-12-310001396814us-gaap:AccumulatedTranslationAdjustmentMember2024-12-310001396814us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2025-01-012025-03-310001396814us-gaap:AccumulatedTranslationAdjustmentMember2025-01-012025-03-310001396814us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2025-03-310001396814us-gaap:AccumulatedTranslationAdjustmentMember2025-03-310001396814us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-12-310001396814us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310001396814us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-01-012024-03-310001396814us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-03-310001396814us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-03-310001396814us-gaap:AccumulatedTranslationAdjustmentMember2024-03-3100013968142024-05-0700013968142024-05-102024-05-1000013968142024-05-100001396814us-gaap:SubsequentEventMember2025-04-1700013968142023-06-012023-06-300001396814pcrx:InducementPlan2014Member2014-04-300001396814pcrx:InducementPlan2014Member2023-12-012023-12-310001396814pcrx:InducementPlan2014Member2024-09-012024-09-300001396814pcrx:InducementPlan2014Member2024-09-300001396814pcrx:InducementPlan2014Member2025-01-012025-01-310001396814pcrx:InducementPlan2014Member2025-01-310001396814us-gaap:CostOfSalesMember2025-01-012025-03-310001396814us-gaap:CostOfSalesMember2024-01-012024-03-310001396814us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001396814us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310001396814us-gaap:SellingGeneralAndAdministrativeExpensesMember2025-01-012025-03-310001396814us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-03-310001396814pcrx:ContingentConsiderationGainLossRestructuringChargesAndOtherMember2025-01-012025-03-310001396814pcrx:ContingentConsiderationGainLossRestructuringChargesAndOtherMember2024-01-012024-03-310001396814us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001396814us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001396814us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001396814us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001396814us-gaap:EmployeeStockMember2025-01-012025-03-310001396814us-gaap:EmployeeStockMember2024-01-012024-03-310001396814us-gaap:RestrictedStockUnitsRSUMember2024-12-310001396814us-gaap:RestrictedStockUnitsRSUMember2025-03-310001396814us-gaap:AccountingStandardsUpdate202006Member2025-01-012025-03-310001396814us-gaap:AccountingStandardsUpdate202006Member2024-01-012024-03-310001396814us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001396814us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001396814us-gaap:SeniorNotesMember2025-01-012025-03-310001396814us-gaap:SeniorNotesMember2024-01-012024-03-310001396814us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001396814us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001396814us-gaap:EmployeeStockMember2025-01-012025-03-310001396814us-gaap:EmployeeStockMember2024-01-012024-03-310001396814pcrx:FlexionTherapeuticsIncMember2025-01-012025-03-310001396814pcrx:FlexionTherapeuticsIncMember2024-01-012024-03-310001396814pcrx:EXPARELMember2024-02-012024-02-290001396814pcrx:IoveraMember2024-02-012024-02-290001396814pcrx:LongTermGrowthMemberus-gaap:EmployeeSeveranceMember2023-12-310001396814pcrx:LongTermGrowthMemberus-gaap:ContractTerminationMember2023-12-310001396814pcrx:LongTermGrowthMember2023-12-310001396814pcrx:LongTermGrowthMemberus-gaap:EmployeeSeveranceMember2024-01-012024-12-310001396814pcrx:LongTermGrowthMemberus-gaap:ContractTerminationMember2024-01-012024-12-310001396814pcrx:LongTermGrowthMember2024-01-012024-12-310001396814pcrx:LongTermGrowthMemberus-gaap:EmployeeSeveranceMember2024-12-310001396814pcrx:LongTermGrowthMemberus-gaap:ContractTerminationMember2024-12-310001396814pcrx:LongTermGrowthMember2024-12-310001396814pcrx:LongTermGrowthMemberus-gaap:EmployeeSeveranceMember2025-01-012025-03-310001396814pcrx:LongTermGrowthMemberus-gaap:ContractTerminationMember2025-01-012025-03-310001396814pcrx:LongTermGrowthMember2025-01-012025-03-310001396814pcrx:LongTermGrowthMemberus-gaap:EmployeeSeveranceMember2025-03-310001396814pcrx:LongTermGrowthMemberus-gaap:ContractTerminationMember2025-03-310001396814pcrx:LongTermGrowthMember2025-03-310001396814us-gaap:EmployeeSeveranceMember2024-01-012024-12-310001396814pcrx:PatentInfringementMember2025-01-012025-03-310001396814pcrx:ResearchDevelopmentFoundationMember2023-08-310001396814pcrx:BaylorCollegeOfMedicineBaylorMembersrt:MinimumMember2017-01-012017-12-310001396814pcrx:BaylorCollegeOfMedicineBaylorMembersrt:MaximumMember2017-01-012017-12-310001396814pcrx:ReportableSegmentMember2025-01-012025-03-310001396814pcrx:ReportableSegmentMember2024-01-012024-03-31

(Exact Name of Registrant as Specified in its Charter)

 

(Address and Zip Code of Principal Executive Offices)

(Registrant’s Telephone Number, Including Area Code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol

Name of each exchange on which registered

Common Stock, par value $0.001 per share

PCRX

Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes  ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.) ☒ Yes  ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes  ☒ No

As of May 7, 2025, 46,304,667 shares of the registrant’s common stock, $0.001 par value per share, were outstanding.

						Page #
PART I. FINANCIAL INFORMATION						4
Item 1.			Financial Statements (Unaudited)			4
			Condensed Consolidated Balance Sheets			4
			Condensed Consolidated Statements of Operations			5
			Condensed Consolidated Statements of Comprehensive Income			6
			Condensed Consolidated Statements of Stockholders’ Equity			7
			Condensed Consolidated Statements of Cash Flows			8
			Notes to Condensed Consolidated Financial Statements			9
Item 2.			Management’s Discussion and Analysis of Financial Condition and Results of Operations			34
Item 3.			Quantitative and Qualitative Disclosures About Market Risk			50
Item 4.			Controls and Procedures			50
PART II. OTHER INFORMATION						51
Item 1.			Legal Proceedings			52
Item 1A.			Risk Factors			52
Item 2.			Unregistered Sales of Equity Securities and Use of Proceeds			52
Item 3.			Defaults Upon Senior Securities			52
Item 4.			Mine Safety Disclosures			52
Item 5.			Other Information			52
Item 6.			Exhibits			52
Signatures						54

Item 1. FINANCIAL STATEMENTS (Unaudited)

									Three Months Ended March 31,
															2025						2024
Revenues:
Net product sales															$	167,594					$	165,824
Royalty revenue															1,329						1,293
Total revenues															168,923						167,117
Operating expenses:
Cost of goods sold															34,306						47,416
Research and development															25,342						18,238
Selling, general and administrative															86,776						72,026
Amortization of acquired intangible assets															14,322						14,322
Contingent consideration gains, acquisition-related expenses, restructuring and other															6,187						1,903
Total operating expenses															166,933						153,905
Income from operations															1,990						13,212
Other income (expense):
Interest income															6,895						3,903
Interest expense															(4,580)						(3,316)
Other, net															4,401						(159)
Total other income, net															6,716						428
Income before income taxes															8,706						13,640
Income tax expense															(3,894)						(4,661)
Net income															$	4,812					$	8,979
Net income per common share:
Basic and diluted net income per common share															$	0.10					$	0.19
Weighted average common shares outstanding:
Basic															46,275						46,499
Diluted															46,526						52,193

    

 

 

			Number of Shares Outstanding																								Additional Paid-In Capital						Accumulated Deficit						Accumulated Other Comprehensive Income
			Common Shares						Treasury Shares						Common Stock						Treasury Stock																								Total
Balance at December 31, 2024			47,078						(837)						$	47					$	(25,121)					$	1,009,435					$	(206,356)					$	343					$	778,348
Vested restricted stock units			53						—						—						—						1						—						—						1
Common stock withheld for employee withholding tax liabilities on vested restricted stock units			(10)						—						—						—						(181)						—						—						(181)
Stock-based compensation			—						—						—						—						14,553						—						—						14,553
Other comprehensive income (Note 11)			—						—						—						—						—						—						1,008						1,008
Net income			—						—						—						—						—						4,812						—						4,812
Balance at March 31, 2025			47,121						(837)						$	47					$	(25,121)					$	1,023,808					$	(201,544)					$	1,351					$	798,541

Pacira BioSciences, Inc. and its subsidiaries (collectively, the “Company” or “Pacira”) delivers innovative, non-opioid pain therapies to transform the lives of patients. The Company’s long-acting, local analgesic, EXPAREL® (bupivacaine liposome injectable suspension), was commercially launched in the United States, or U.S., in April 2012 and approved in select European countries and the United Kingdom, or U.K., in November 2021. EXPAREL utilizes the Company’s proprietary multivesicular liposome, or pMVL, drug delivery technology that encapsulates drugs without altering their molecular structure and releases them over a desired period of time. EXPAREL is currently indicated to produce postsurgical local analgesia via infiltration in patients aged six years and older, and postsurgical regional analgesia via an interscalene brachial plexus block in adults, a sciatic nerve block in the popliteal fossa in adults, and an adductor canal block in adults for postsurgical pain management (the safety and effectiveness of EXPAREL have not been established to produce postsurgical regional analgesia via other nerve blocks besides an interscalene brachial plexus nerve block, a sciatic nerve block in the popliteal fossa, or an adductor canal block). In November 2021, the Company acquired Flexion Therapeutics, Inc., or Flexion (the “Flexion Acquisition”), and added ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) to its product portfolio. ZILRETTA is the first and only extended-release, intra-articular (meaning in the joint) injection indicated for the management of osteoarthritis, or OA, knee pain. In April 2019, the Company added iovera®° to its commercial offering with the acquisition of MyoScience, Inc., or MyoScience (the “MyoScience Acquisition”). The iovera° system is a handheld cryoanalgesia device that delivers immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201 (enekinragene inzadenovec), a novel, locally administered gene therapy for the treatment of osteoarthritis, or OA, of the knee. PCRX-201 is the lead program from the Company’s proprietary high-capacity adenovirus, or HCAd, vector platform, which enables local administration of genetic medicines and has the potential to unlock gene therapy for large prevalent diseases affecting millions of people. In February 2025, the Company acquired the remaining 81 percent equity interest in GQ Bio Therapeutics GmbH, or GQ Bio (the “GQ Bio Acquisition”), a privately-held biopharmaceutical company, which included the novel HCAd platform, a preclinical portion of HCAd-based assets and research and development talent. For more information on the GQ Bio Acquisition, see Note 3, GQ Bio Therapeutics Acquisition.

Pacira is subject to risks common to companies in similar industries and stages, including, but not limited to, competition from larger companies and potential generic entrants, reliance on revenue from three products, reliance on a limited number of wholesalers, reliance on a limited number of manufacturing sites, new technological innovations, dependence on key personnel, reliance on third-party service providers and sole source suppliers, protection of proprietary technology, compliance with government regulations and risks related to cybersecurity.

These interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and in accordance with the rules and regulations of the United States Securities and Exchange Commission, for interim reporting. Pursuant to these rules and regulations, certain information and footnote disclosures normally included in complete annual financial statements have been condensed or omitted. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 (the “2024 Annual Report”).

The condensed consolidated financial statements at March 31, 2025, and for the three-month periods ended March 31, 2025 and 2024, are unaudited, but include all adjustments (consisting of only normal recurring adjustments) which, in the opinion of management, are necessary to present fairly the financial information set forth herein in accordance with GAAP. The condensed consolidated balance sheet at December 31, 2024 is derived from the audited consolidated financial statements included in the Company’s 2024 Annual Report. The accounts of wholly-owned subsidiaries are included in the condensed consolidated financial statements. Intercompany accounts and transactions have been eliminated in consolidation.

The results of operations for these interim periods are not necessarily indicative of results that may be expected for any other interim periods or for the full year.

The table below includes the percentage of revenues comprised by the Company’s three largest wholesalers in each period presented:

In November 2023, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures. The ASU amendment improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses on an interim and annual basis. The new segment disclosure requirements apply for entities with a single reportable segment. The Company adopted the standard for its interim and annual reporting which was applied retrospectively for all prior periods presented. The ASU's amendment is effective for interim periods in fiscal years beginning after December 15, 2024. Refer to Note 17, Segment Information, for more information.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures. The ASU amendment addresses investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The ASU’s amendments are effective for fiscal years beginning after December 15, 2024 and may be adopted on a prospective or retrospective basis. The Company is currently evaluating the impact of adopting ASU 2023-09 on its consolidated financial statements.

In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40), Disaggregation of Income Statement Expenses. The ASU amendment improves financial reporting by requiring public business entities to disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The ASU’s amendments are effective for annual reporting periods beginning after December 31, 2026 and interim periods beginning after December 15, 2027, with early adoption permitted. This ASU amendment can be applied on a prospective basis or retrospectively. The Company is currently evaluating the impact of adopting ASU 2024-03 on its footnote disclosures.

On February 25, 2025, Pacira Therapeutics, Inc., a wholly-owned subsidiary of the Company, entered into a securities purchase agreement to acquire the remaining 81% of GQ Bio for $30.3 million, net of working capital adjustments. Prior to the GQ Bio Acquisition, the Company owned approximately 19% of GQ Bio. Included in the securities purchase agreement are payments of $7.8 million related to employee compensation to be recognized over three years pursuant to a key employee holdback agreement. During the three months ended March 31, 2025, the Company expensed $0.3 million within contingent consideration gains, acquisition-related expenses, restructuring and other within the condensed consolidated statement of operations.

GQ Bio was a privately-held biopharmaceutical company with a novel, high-capacity, local-delivery platform that makes genetic medicines more efficient and enables the use of large and multiple gene constructs. PCRX-201 is the lead program from this platform. By acquiring GQ Bio, the Company benefits from further developing PCRX-201 and the cost savings associated with no longer being obligated to make milestone and royalty payments, as well as establishing a research and development engine with a dedicated workforce focused on this next-generation of genetic medicine and acquiring a portfolio of preclinical assets.

The following table reconciles the purchase price for the remaining 81% ownership to the total fair value of the GQ Bio Acquisition (in thousands):

The Company has accounted for the GQ Bio Acquisition using the acquisition method of accounting and, accordingly, has included the assets acquired, liabilities assumed and results of operations in its condensed consolidated financial statements from the acquisition date of February 27, 2025. A $6.5 million indemnification holdback established for potential unidentified liabilities will be settled within 18 months from the acquisition date. In conjunction with the GQ Bio Acquisition, the settlement of the Company’s prior equity investment and notes receivable in GQ Bio were part of the fair value of consideration exchanged. See Note 10, Financial Instruments, for additional information.

The preliminary purchase price allocation is based on estimates, assumptions, valuations and other studies which have not yet been finalized. Prior to the finalization of the purchase price allocation, if information becomes available that would indicate it is probable that unknown events had occurred and the amounts can be reasonably estimated, such items will be included in the final purchase price allocation and may change the carrying value of goodwill. The Company is finalizing its valuation of intangible assets, tangible assets, liabilities and tax analyses, and anticipates finalizing the purchase price allocation as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date.

The following tables set forth the preliminary allocation of the GQ Bio Acquisition purchase price to the estimated fair value of the net assets acquired at the acquisition date (in thousands):

The acquired identifiable IPR&D assets were valued from a market participants’ perspective using a multi-period excess earnings methodology (income approach). The IPR&D asset relates to further developing PCRX-201 and the cost savings associated with milestone and royalty payments. The projected cash flows for this IPR&D asset were adjusted for the probability of successful development and commercialization, and were discounted at 20.0%.

The excess of the purchase price over the fair value of identifiable net assets acquired represents goodwill. This goodwill is primarily attributable to the value in establishing a research and development engine focused on supporting products akin to PCRX-201, assembling a dedicated workforce within a niche industry, obtained preclinical assets, as well as the synergies of merging operations. The acquired goodwill and IPR&D intangible asset are currently not deductible for tax purposes. However, the Company is considering certain tax elections that would allow for the future deduction of the acquired goodwill and IPR&D intangible asset.

During the three months ended March 31, 2025, GQ Bio did not earn any revenue and the operating loss attributable to GQ Bio was considered nominal.

The Company’s net product sales consist of (i) EXPAREL in the U.S., the European Union, or E.U., and the U.K.; (ii) ZILRETTA in the U.S.; (iii) iovera° in the U.S., Canada and Europe and (iv) sales of its bupivacaine liposome injectable suspension for veterinary use. Royalty revenues are related to a collaborative licensing agreement from the sale of the Company’s bupivacaine liposome injectable suspension for veterinary use. The Company does not consider revenue from sources other than sales of EXPAREL and ZILRETTA to be material sources of its consolidated revenue. As such, the following disclosure is limited to revenue associated with net product sales of EXPAREL and ZILRETTA.

The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers based on orders of the product placed by end-users, namely hospitals, ambulatory surgery centers and healthcare provider offices. EXPAREL is delivered directly to the end-user without the wholesaler ever taking physical possession of the product. The Company primarily sells ZILRETTA to specialty distributors and specialty pharmacies, who then subsequently resell

ZILRETTA to physicians, clinics and certain medical centers or hospitals. The Company also contracts directly with healthcare providers and intermediaries such as group purchasing organizations, or GPOs. Product revenue is recognized when control of the promised goods are transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for transferring those goods. EXPAREL and ZILRETTA revenue is recorded at the time the products are transferred to the customer.

Revenues from sales of products are recorded net of returns allowances, prompt payment discounts, service fees, government rebates, volume rebates and chargebacks. These reserves are based on estimates of the amounts earned or to be claimed on the related sales. These amounts are treated as variable consideration, estimated and recognized as a reduction of the transaction price at the time of the sale, using the most likely amount method, except for returns, which is based on the expected value method. The Company includes these estimated amounts in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized for such transaction will not occur, or when the uncertainty associated with the variable consideration is resolved.

Chargebacks for fees and discounts represent the estimated obligations resulting from contractual commitments to sell products to Department of Veteran Affairs hospitals, participating GPO members, 340B qualified entities and other contracted customers at prices lower than the list price. The 340B Drug Discount Program is a U.S. federal government program that requires participating drug manufacturers to provide outpatient drugs to eligible health care organizations and covered entities at reduced prices. Customers claim the difference between the amount invoiced and the discounted selling price through a chargeback issued by a wholesaler. Reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and trade receivables, net. Chargeback amounts are determined at the time of sale and the Company generally issues credits for such amounts within weeks of receiving notification from a wholesaler. Reserves for chargebacks consist of anticipated credits the Company expects to issue based on expected units sold and chargebacks that customers have claimed for which credits have not yet been issued.

The calculation for some of these items requires management to make estimates based on sales data, historical return data, contracts, statutory requirements and other related information that may become known in the future. The adequacy of these provisions is reviewed on a quarterly basis.

The majority of accounts receivable arise from product sales and represent amounts due from wholesalers, hospitals, ambulatory surgery centers, specialty distributors, specialty pharmacies and individual physicians. Payment terms generally range from zero to four months from the date of the transaction, and accordingly, there is no significant financing component.

A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in Accounting Standards Codification 606. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.

At contract inception, the Company assesses the goods promised in its contracts with customers and identifies a performance obligation for each promise to transfer to the customer a good that is distinct. When identifying individual performance obligations, the Company considers all goods promised in the contract regardless of whether explicitly stated in the customer contract or implied by customary business practices. The Company’s contracts with customers require it to transfer an individual distinct product, which represents a single performance obligation. The Company’s performance obligation with respect to its product sales is satisfied at a point in time, which transfers control upon delivery of EXPAREL and ZILRETTA to its customers. The Company considers control to have transferred upon delivery because the customer has legal title to the asset, physical possession of the asset has been transferred, the customer has significant risks and rewards of ownership of the asset and the Company has a present right to payment at that time.

The following table represents disaggregated net product sales in the periods presented as follows (in thousands):

									Three Months Ended March 31,
															2025						2024
Net product sales:
EXPAREL															$	136,529					$	132,430
ZILRETTA															23,338						25,839
iovera°															5,123						5,030
Bupivacaine liposome injectable suspension															2,604						2,525
Total net product sales															$	167,594					$	165,824

The components of inventories, net are as follows (in thousands):

Fixed assets, net, summarized by major category, consist of the following (in thousands):

(1) In April 2025, subsequent to the three months ended March 31, 2025, a ZILRETTA fill line at the Company’s manufacturing facility in Swindon, UK, was placed into service, for which approximately $23.1 million was reclassified from construction in progress to machinery and equipment, leasehold improvements and computer equipment and software.

For the three months ended March 31, 2025 and 2024, depreciation expense was $6.8 million and $4.1 million, respectively. For the three months ended March 31, 2025 and 2024, there was $0.1 million and $0.7 million of capitalized interest on the construction of manufacturing sites, respectively.

As of March 31, 2025 and December 31, 2024, total fixed assets, net, includes manufacturing process equipment and leasehold improvements located outside of the U.S. in the amount of $50.0 million and $51.1 million, respectively.

As of March 31, 2025 and December 31, 2024, the Company had asset retirement obligations of $4.3 million and $4.2 million, respectively, included in accrued expenses and other liabilities on its condensed consolidated balance sheets, for costs associated with returning leased spaces to their original condition upon the termination of certain of its lease agreements.

The Company leases all of its facilities, including its EXPAREL and iovera° handpiece manufacturing facility at its Science Center Campus in San Diego, California. The Company also has two embedded leases with Thermo Fisher Scientific Pharma Services for the use of their manufacturing facility in Swindon, U.K. for the production of EXPAREL and ZILRETTA. A portion of the associated monthly base fees have been allocated to the lease components based on a relative fair value basis. The Company’s European offices were assumed as part of the GQ Bio Acquisition in February 2025 and include an administrative office in Hamburg, Germany, a research and development lab and offices in Luckenwalde, Germany and an administrative office in each of Eupen and Liège, Belgium. As a result of the GQ Bio Acquisition, the Company recorded new operating right of use assets and lease liabilities in the amount of $1.4 million.

The Company had been recognizing sublease income for laboratory space leased in Woburn, Massachusetts and a portion of office space leased in Burlington, Massachusetts, respectively, from leases that were assumed as part of the Flexion Acquisition. In February 2024, the lease and sublease term concluded for the laboratory space in Woburn, Massachusetts. In April 2025, the lease and sublease term concluded for the office space in Burlington, Massachusetts.

The operating lease costs for the facilities include lease and non-lease components, such as common area maintenance and other common operating expenses, along with executory costs such as insurance and real estate taxes. Total operating lease expense, net is as follows (in thousands):

Supplemental cash flow information related to operating leases is as follows (in thousands):

The Company has elected to net the amortization of the right-of-use asset and the reduction of the lease liability principal in other liabilities in the condensed consolidated statements of cash flows.

The Company has measured its operating lease liabilities at an estimated discount rate at which it could borrow on a collateralized basis over the remaining term for each operating lease. The weighted average remaining lease terms and the weighted average discount rates are summarized as follows:

						March 31,
						2025						2024
Weighted average remaining lease term						5.01 years						5.81 years
Weighted average discount rate						6.92		%				7.01		%

Maturities of the Company’s operating lease liabilities are as follows (in thousands):

The Company’s goodwill arose from the GQ Bio Acquisition in February 2025. The change in the carrying value of the Company’s goodwill is summarized as follows (in thousands):

Intangible assets, net, consists of the in-process research and development, or IPR&D, from the GQ Bio Acquisition and Flexion Acquisition, developed technology from the Flexion Acquisition and MyoScience Acquisition and customer relationships from the MyoScience Acquisition are summarized as follows (dollar amounts in thousands):

Amortization expense on intangible assets was $14.3 million for both the three months ended March 31, 2025 and 2024.

Assuming no changes in the gross carrying amount of these intangible assets, the future estimated amortization expense on the finite-lived intangible assets will be $43.0 million for the remaining nine months of 2025, $57.3 million each year from 2026 to 2030, $37.4 million in 2031, $7.9 million in 2032 and $2.2 million in 2033.

The carrying value of the Company’s outstanding debt is summarized as follows (in thousands):

On March 31, 2023, the Company entered into a credit agreement (as amended and/or restated to date, the “TLA Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders, to refinance the indebtedness outstanding under the Company’s then-existing TLB Credit Agreement (as defined and discussed below). The term loan issued under the TLA Credit Agreement (the “TLA Term Loan”) was issued at a 0.30% discount and provides for a single-advance term loan A facility in the principal amount of $150.0 million, which is secured by substantially all of the Company’s and any subsidiary guarantor’s assets. Subject to certain conditions, the Company may, at any time, on one or more occasion, add one or more new classes of term facilities and/or increase the principal amount of the loans of any existing class by requesting one or more incremental term facilities. The net proceeds of the TLA Term Loan were approximately $149.6 million after deducting an original issue discount of $0.4 million.

On May 8, 2024, the Company, JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders entered into a first amendment (the “First TLA Amendment”) to the TLA Credit Agreement. The First TLA Amendment, among other things, permits the Company’s share repurchase program and the Capped Call Transactions (as defined and described below).

The total debt composition of the TLA Term Loan is as follows (in thousands):

The TLA Term Loan matures on March 31, 2028 and the TLA Credit Agreement requires quarterly repayments of principal in the amount of $2.8 million which commenced on June 30, 2023, increasing to $3.8 million commencing March 31, 2025, with a remaining balloon payment of approximately $85.3 million due at maturity. Due to voluntary principal prepayments, the Company is not required to make further principal payments until December 2026, although the Company retains the option to do so.

The TLA Credit Agreement requires the Company to, among other things, maintain (i) a Senior Secured Net Leverage Ratio (as defined in the TLA Credit Agreement), determined as of the last day of each fiscal quarter, of no greater than 3.00 to 1.00 and (ii) a Fixed Charge Coverage Ratio (as defined in the TLA Credit Agreement), determined as of the last day of each fiscal quarter, of no less than 1.50 to 1.00. The TLA Credit Agreement requires the Company to maintain an unrestricted cash and cash equivalents balance of at least $300.0 million ($500.0 million less a $200.0 million prepayment of the 2025 Notes in the year ended December 31, 2024) less any additional prepayments of the 2025 Notes (as defined below) at any time from 91 days prior to the maturity date through the earlier of (i) the latest maturity date of the 2025 Notes and (ii) the date on which there is no outstanding principal amount of the 2025 Notes. The TLA Credit Agreement also contains customary affirmative and negative covenants, financial covenants, representations and warranties, events of default and other provisions. As of March 31, 2025, the Company was in compliance with all financial covenants under the TLA Credit Agreement.

The Company may elect to borrow either (i) alternate base rate borrowings or (ii) term benchmark borrowings or daily simple SOFR (as defined in the TLA Credit Agreement) borrowings. Each term loan borrowing that is an alternate base rate

borrowing bears interest at a rate per annum equal to (i) the Alternate Base Rate (as defined in the TLA Credit Agreement), plus (ii) a spread based on the Company’s Senior Secured Net Leverage Ratio ranging from 2.00% to 2.75%. Each term loan borrowing that is a term benchmark borrowing or daily simple SOFR borrowing bears interest at a rate per annum equal to (i) the Adjusted Term SOFR Rate or Adjusted Daily Simple SOFR (as each is defined in the Credit Agreement), plus (ii) a spread based on the Company’s Senior Secured Net Leverage Ratio ranging from 3.00% to 3.75%. During the three months ended March 31, 2025, the Company made $2.8 million of voluntary principal prepayments. During the year ended December 31, 2024, the Company made $11.3 million of voluntary principal prepayments. As of March 31, 2025, borrowings under the TLA Term Loan consisted entirely of term benchmark borrowings at a rate of 7.40%.

In May 2024, the Company completed a private placement of $287.5 million in aggregate principal amount of its 2.125% convertible senior notes due 2029, or 2029 Notes, and entered into an indenture with Computershare Corporate Trust, N.A., or 2029 Indenture, with respect to the 2029 Notes. The 2029 Notes accrue interest at a fixed rate of 2.125% per year, payable semiannually in arrears on May 15th and November 15th of each year. The 2029 Notes mature on May 15, 2029.

The total debt composition of the 2029 Notes is as follows (in thousands):

Holders may convert their 2029 Notes prior to the close of business on the business day immediately preceding November 15, 2028, only if certain circumstances are met, including, but not limited to, if during the previous calendar quarter, the last reported sales price of the Company’s common stock was greater than 130% of the conversion price then applicable for at least 20 out of the last 30 consecutive trading days of the quarter. During the quarter ended March 31, 2025, the conditions for conversion were not met. On or after November 15, 2028, until the close of business on the second scheduled trading day immediately preceding May 15, 2029, holders may convert their 2029 Notes at any time.

Upon conversion, holders will receive the principal amount of their 2029 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the 50 consecutive trading days during the observation period (as more fully described in the 2029 Indenture). For the principal, the Company will settle in cash per the terms of the 2029 Notes. For any excess conversion value, holders may receive cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock, at the Company’s option. The initial conversion rate for the 2029 Notes is 25.2752 shares of common stock per $1,000 principal amount, which is equivalent to an initial conversion price of $39.56 per share of the Company’s common stock. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2029 Notes represents a premium of approximately 32.5% to the closing sale price of $29.86 per share of the Company’s common stock on the Nasdaq Global Select Market on May 9, 2024, the date that the Company priced the private offering of the 2029 Notes.

As of March 31, 2025, the 2029 Notes had a market price of $973 per $1,000 principal amount. In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of further stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2029 Notes will be paid pursuant to the terms of the 2029 Indenture. In the event that all of the 2029 Notes are converted, the Company would be required to repay the $287.5 million in principal value in cash, whereas any conversion premium would be required to be repaid in any combination of cash and shares of its common stock (at the Company’s option).

Prior to the close of business on the business day immediately preceding November 15, 2028, the 2029 Notes are convertible only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2024 (and only during such calendar quarter), if the last reported sale price of the Common Stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is equal to or greater than 130% of the conversion price on each applicable trading day; (2) during the five business-day period after any five consecutive trading-day period (the “measurement period”) in which the trading price per $1,000 principal amount of the 2029 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such trading day; (3) upon the occurrence of specified corporate events; or (4) upon a Company redemption. On or after November 15, 2028,

until the close of business on the second scheduled trading day immediately preceding May 15, 2029, holders of the 2029 Notes may convert all or a portion of their 2029 Notes, at any time. No sinking fund is provided for the 2029 Notes.

On or after May 17, 2027 and on or before the 50th scheduled trading day immediately before the maturity date, the Company may redeem for cash all or part of the 2029 Notes if (i) the 2029 Notes are “freely tradable” (as defined in the 2029 Indenture) and any accrued and unpaid additional interest has been paid as of the date the Company sends the related notice of the redemption and (ii) the last reported sales price of the Company’s common stock exceeds 130% of the conversion price then in effect for (1) each of at least 20 trading days (whether or not consecutive) during any 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related notice of the redemption; and (2) the trading day immediately before the date the Company sends such notice. The redemption price of each 2029 Note to be redeemed will be the principal amount of such 2029 Note, plus accrued and unpaid interest, if any. In addition, calling any 2029 Notes for redemption will constitute a make-whole fundamental change, in which case the conversion rate applicable to those 2029 Notes, if converted in connection with the redemption, will be increased in certain circumstances. Upon the occurrence of a “make-whole fundamental change” (as defined in the 2029 Indenture), subject to a limited exception for certain cash mergers, holders may require the Company to repurchase all or a portion of their 2029 Notes for cash at a price equal to 100% of the principal amount of the 2029 Notes to be repurchased plus any accrued and unpaid interest.

While the 2029 Notes are currently classified on the Company’s condensed consolidated balance sheet at March 31, 2025 as long-term debt, the future convertibility and resulting balance sheet classification of this liability is monitored at each quarterly reporting date and is analyzed dependent upon market prices of the Company’s common stock during the prescribed measurement periods. In the event that the holders of the 2029 Notes have the election to convert the 2029 Notes at any time during the prescribed measurement period, the 2029 Notes would then be considered a current obligation and classified as such.

On May 9, 2024, in connection with the pricing of the 2029 Notes, and on May 10, 2024, in connection with the exercise in full by the initial purchasers of the 2029 Notes (the “Initial Purchasers”) of their option to purchase additional 2029 Notes, the Company entered into privately negotiated capped call transactions (the “Capped Call Transactions”) with certain of the Initial Purchasers of the 2029 Notes and/or their respective affiliates and/or other financial institutions (the “Option Counterparties”). The Capped Call Transactions are expected to cover, subject to anti-dilution adjustments substantially similar to those applicable to the 2029 Notes, the number of shares of the Company’s common stock underlying the 2029 Notes.

The Capped Call Transactions are expected to reduce the potential dilution to the Company’s common stock upon any conversion of the 2029 Notes and/or offset any potential cash payments the Company is required to make in excess of the principal amount of converted 2029 Notes, as the case may be, upon any conversion of the 2029 Notes, with such reduction and/or offset subject to a cap. The cap price of the Capped Call Transactions will initially be approximately $53.75 per share, representing a premium of approximately 80% over the closing price of $29.86 per share of the Company’s common stock on May 9, 2024, and is subject to certain adjustments under the terms of the Capped Call Transactions. The capped call was recorded as a reduction to additional paid-in capital at its cost of $26.7 million, partially offset by a $6.5 million deferred tax asset.

The Capped Call Transactions are separate transactions entered into by the Company with the Option Counterparties, are not part of the terms of the 2029 Notes and will not affect any holder’s rights under the 2029 Notes. Holders of the 2029 Notes will not have any rights with respect to the Capped Call Transactions.

In July 2020, the Company completed a private placement of $402.5 million in aggregate principal amount of 0.750% convertible senior notes due 2025, or 2025 Notes, and entered into an indenture with Computershare Corporate Trust, N.A. (formerly Wells Fargo Bank, N.A.), or 2025 Indenture, with respect to the 2025 Notes. The 2025 Notes accrue interest at a fixed rate of 0.750% per year, payable semiannually in arrears on February 1st and August 1st of each year. The 2025 Notes mature on August 1, 2025.

In May 2024, the Company used part of the net proceeds from the issuance of the 2029 Notes to repurchase $200.0 million aggregate principal amount of the 2025 Notes in privately negotiated transactions at a discount for $191.4 million in cash (including accrued interest). The partial repurchase of the 2025 Notes resulted in a $7.5 million gain on early extinguishment of debt during the year ended December 31, 2024.

The total debt composition of the 2025 Notes is as follows (in thousands):

			March 31,						December 31,
			2025						2024
0.750% convertible senior notes due August 2025			$	202,500					$	202,500
Deferred financing costs			(414)						(724)
Total debt, net of deferred financing costs			$	202,086					$	201,776

Holders were able to convert their 2025 Notes at any time prior to the close of business on the business day immediately preceding February 3, 2025, only under the following circumstances: (i) during any calendar quarter (and only during such calendar quarter), if the last reported sales price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (ii) during the five-business day period immediately after any five consecutive trading day period (the “measurement period”) in which the trading price (as defined in the 2025 Indenture) per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such trading day; (iii) upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of the Company’s assets; or (iv) if the Company calls the 2025 Notes for redemption, until the close of business on the business day immediately preceding the redemption date. These conditions for conversion were not met prior to February 3, 2025.

As of February 3, 2025, until the close of business on the second scheduled trading day immediately preceding August 1, 2025, holders may convert their 2025 Notes at any time.

Upon conversion, holders will receive the principal amount of their 2025 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the 40 consecutive trading days during the observation period (as more fully described in the 2025 Indenture). For both the principal and excess conversion value, holders may receive cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock, at the Company’s option. The initial conversion rate for the 2025 Notes is 13.9324 shares of common stock per $1,000 principal amount, which is equivalent to an initial conversion price of $71.78 per share of the Company’s common stock. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2025 Notes represents a premium of approximately 32.5% to the closing sale price of $54.17 per share of the Company’s common stock on the Nasdaq Global Select Market on July 7, 2020, the date that the Company priced the private offering of the 2025 Notes.

As of March 31, 2025, the 2025 Notes had a market price of $986 per $1,000 principal amount. In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of further stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2025 Notes will be paid pursuant to the terms of the 2025 Indenture. In the event that all of the 2025 Notes are converted, the Company would be required to repay the remaining $202.5 million in principal value and any conversion premium in any combination of cash and shares of its common stock (at the Company’s option).

Since August 1, 2023 (but, in the case of a redemption of less than all of the outstanding 2025 Notes, no later than the 40th scheduled trading day immediately before the maturity date), the Company may redeem for cash all or part of the 2025 Notes if the last reported sale price (as defined in the 2025 Indenture) of the Company’s common stock has been at least 130% of the conversion price then in effect for (i) each of at least 20 trading days (whether or not consecutive) during any 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related notice of redemption and (ii) the trading day immediately before the date the Company sends such notice. The redemption price will equal the sum of (i) 100% of the principal amount of the 2025 Notes being redeemed, plus (ii) accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date. In addition, calling the 2025 Notes for redemption will constitute a “make-whole fundamental change” (as defined in the 2025 Indenture) and will, in certain circumstances, increase the conversion rate applicable to the conversion of such notes if it is converted in connection with the redemption. No sinking fund is provided for the 2025 Notes.

Prior to the Flexion Acquisition, in May 2017, Flexion issued an aggregate of $201.3 million principal amount of 3.375% convertible senior notes due May 1, 2024 (the “Flexion 2024 Notes”), pursuant to an indenture between Flexion and Computershare Corporate Trust, N.A. (formerly Wells Fargo Bank, N.A.), as trustee (the “Flexion Trustee”), as supplemented by the First Supplemental Indenture, dated as of November 19, 2021, between Flexion and the Flexion Trustee. Interest was

payable semi-annually on May 1st and November 1st of each year. Upon the Flexion Acquisition, the principal was assumed and recorded at fair value by the Company.

On January 7, 2022, following the expiration of the offer to purchase, the Company accepted the $192.6 million aggregate principal amount of Flexion 2024 Notes that were validly tendered (and not validly withdrawn). No Flexion 2024 Notes were converted in connection with the Notice. The remaining principal of $8.6 million was repaid at maturity on May 1, 2024.

The following table sets forth the total interest expense recognized in the periods presented (dollar amounts in thousands):

Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in the principal or most advantageous market in an orderly transaction. To increase consistency and comparability in fair value measurements, the FASB established a three-level hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of fair value measurements are:

•Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

•Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.

•Level 3: Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

The carrying value of financial instruments including cash and cash equivalents, accounts receivable and accounts payable approximate their respective fair values due to the short-term nature of these items. The fair value of the Company’s convertible senior notes and its TLA Term Loan are calculated utilizing market quotations from an over-the-counter trading market for these notes (Level 2). The fair value of the Company’s acquisition-related contingent consideration is reported at fair value on a recurring basis (Level 3). The carrying amounts of equity investments and convertible notes receivable without readily determinable fair values have not been adjusted for either an impairment or upward or downward adjustments based on observable transactions.

At March 31, 2025, the carrying values and fair values of the following financial assets and liabilities were as follows (in thousands):

						Carrying Value						Fair Value Measurements Using
												Level 1						Level 2						Level 3
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:
Financial Assets:
Equity investments						$	11,750					$	—					$	—					$	11,750
Convertible notes receivable						$	8,250					$	—					$	—					$	8,250
Financial Liabilities:
Acquisition-related contingent consideration						$	17,566					$	—					$	—					$	17,566
Financial Liabilities Measured at Amortized Cost:
Term loan A facility due March 2028						$	101,489					$	—					$	101,988					$	—
2.125% convertible senior notes due 2029 (1)						$	279,801					$	—					$	279,594					$	—
0.750% convertible senior notes due 2025 (2)						$	202,086					$	—					$	199,716					$	—

(1) The closing price of the Company’s common stock as reported on the Nasdaq Global Select Market was $24.85 per share on March 31, 2025, compared to a conversion price of $39.56 per share. At March 31, 2025, as the conversion price was above the stock price, the requirements for conversion have not been met.

(2) As of February 3, 2025, the 2025 Notes may be converted at any time until the close of business on the second scheduled trading day immediately preceding August 1, 2025. The maximum conversion on the principal that could have been due on the 2025 Notes is 2.8 million shares of the Company’s common stock, which assumes no increase in the conversion rate for certain corporate events.

The Company holds strategic investments in clinical and preclinical stage privately-held biotechnology companies in the form of equity and convertible note investments. The following investments have no readily determinable fair value and are recorded at cost minus impairment, if any, plus or minus observable price changes of identical or similar investments (in thousands):

(1) In conjunction with the GQ Bio Acquisition, the settlement of the Company’s prior equity investment and notes receivable were part of the fair value of consideration exchanged. Upon acquiring the remaining 81% ownership interest in GQ Bio, the Company remeasured its previously held equity interest to its acquisition-date fair value. The $4.2 million gain resulting from the equity investment was recognized as other, net within the condensed consolidated statement of operations. In settling the notes receivable, the Company recognized $1.7 million in interest income. See Note 3, GQ Bio Therapeutics Acquisition, for information on the GQ Bio Acquisition.

The Company has recognized contingent consideration related to the Flexion Acquisition in the amount of $17.6 million and $20.2 million as of March 31, 2025 and December 31, 2024, respectively.

The Company’s contingent consideration obligations are recorded at their estimated fair values and are revalued each reporting period if and until the related contingencies are resolved. The Company has measured the fair value of its contingent consideration using a Monte Carlo simulation. These inputs include, as applicable, estimated forecasts of revenue and costs and the discount rates used to calculate the present value of estimated future payments. Significant changes may increase or

decrease the probabilities of achieving the related commercial and regulatory events, shorten or lengthen the time required to achieve such events, or increase or decrease estimated forecasts.

In November 2021, the Company completed the Flexion Acquisition, which provided for contingent consideration related to contingent value rights that were issued to Flexion shareholders and certain equity award holders which could aggregate up to a total of $372.3 million if certain regulatory and commercial milestones are met. The aggregate amount was initially $425.5 million prior to the Company’s September 2022 decision to formally discontinue further development of Flexion’s investigational product candidate, PCRX-301. The Company’s obligation to make milestone payments is limited to those milestones achieved through December 31, 2030, and are to be paid within 60 days of the end of the fiscal quarter of achievement. During the three months ended March 31, 2025, the Company recognized contingent consideration gains of $2.7 million due to revisions to the latest discount rates. During the three months ended March 31, 2024, the Company recognized gains of $3.8 million due to adjustments to long-term forecasts which reduced the probability of meeting the sales-based contingent consideration milestones by December 31, 2030, the expiration date for achieving the milestones. These adjustments were recorded within contingent consideration gains, acquisition-related expenses, restructuring and other in the condensed consolidated statements of operations. At March 31, 2025, the weighted average discount rate was 8.2%.

The following table includes the key assumptions used in the valuation of the Company’s contingent consideration:

The change in the Company’s contingent consideration recorded at fair value using Level 3 measurements is as follows (in thousands):

						Contingent Consideration Fair Value
Balance at December 31, 2023						$	24,698
Fair value adjustments and accretion						(4,457)
Balance at December 31, 2024						20,241
Fair value adjustments and accretion						(2,675)
Balance at March 31, 2025						$	17,566

Available-for-Sale Investments

Short-term investments consist of asset-backed securities collateralized by credit card receivables, investment grade commercial paper and corporate, federal agency, government and Yankee bonds with maturities greater than three months, but less than one year. Net unrealized gains and losses (excluding credit losses, if any) from the Company’s short-term investments are reported in other comprehensive income. At March 31, 2025 and December 31, 2024, all of the Company’s short-term and noncurrent investments are classified as available-for-sale investments and are determined to be Level 2 instruments, with the exception of U.S. government bonds, which are measured at fair value using standard industry models with observable inputs. The fair value of the commercial paper is measured based on a standard industry model that uses the three-month U.S. Treasury bill rate as an observable input. The fair value of the asset-backed securities and corporate bonds is principally measured or corroborated by trade data for identical issues in which related trading activity is not sufficiently frequent to be considered a Level 1 input or that of comparable securities. The fair value of U.S. government bonds is based on level 1 trading activity. At the time of purchase, all available-for-sale investments had an “A” or better rating by Standard & Poor’s. 

The following summarizes the Company’s short-term available-for-sale investments at March 31, 2025 and December 31, 2024 (in thousands):

At March 31, 2025, there were no investments available for sale that were materially less than their amortized cost.

The Company elects to recognize its interest receivable separate from its available-for-sale investments. At March 31, 2025 and December 31, 2024, the interest receivable from its available-for-sale investments recognized in prepaid expenses and other current assets was $0.4 million and $0.5 million, respectively.

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term and long-term available-for-sale investments and accounts receivable. The Company maintains its cash and cash equivalents with high-credit quality financial institutions. Such amounts may exceed federally-insured limits.

 As of March 31, 2025, three wholesalers each accounted for over 10% of the Company’s accounts receivable, at 36%, 21% and 19%. At December 31, 2024, three wholesalers each accounted for over 10% of the Company’s accounts receivable, at 34%, 18% and 16%. For additional information regarding the Company’s wholesalers, see Note 2, Summary of Significant Accounting Policies. EXPAREL and ZILRETTA revenues are primarily derived from major wholesalers and specialty distributors that generally have significant cash resources. The Company performs ongoing credit evaluations of its customers as warranted and generally does not require collateral. Allowances for credit losses on the Company’s accounts receivable are maintained based on historical payment patterns, current and estimated future economic conditions, aging of accounts receivable and its write-off history. As of March 31, 2025 and December 31, 2024, there were $0.4 million of allowances for credit losses on the Company’s accounts receivable.

The following tables illustrate the changes in the balances of the Company’s accumulated other comprehensive income for the periods presented (in thousands):

(1) Net of a nominal tax benefit for both the three months ended March 31, 2025 and 2024.

On May 7, 2024, the Company announced that its Board of Directors approved a share repurchase program which authorized the Company to repurchase up to an aggregate of $150.0 million of its outstanding common stock. On May 9, 2024, concurrently with the pricing of the offering of the 2029 Notes, the Company entered into separate privately negotiated agreements with certain of the initial purchasers of the 2029 Notes or their respective affiliates and/or certain other financial institutions to repurchase 837,240 shares of the Company’s common stock for a total cost of $25.1 million, inclusive of $0.1 million of accrued excise tax. The repurchase occurred on May 10, 2024.

On April 17, 2025, the Company announced that its Board of Directors approved a new share repurchase program, which replaced the previously authorized share repurchase program and was effective immediately, which authorizes the Company to repurchase up to an aggregate of $300.0 million of its outstanding common stock. Repurchases under this program may be made at management’s discretion on the open market or through privately negotiated transactions. The share repurchase program may be suspended or discontinued at any time by the Company and has an expiration date of December 31, 2026.

Repurchases of the Company’s common stock are accounted for at cost and recorded as treasury stock. The excise tax on repurchases of the Company’s common stock is recorded as a cost of acquiring treasury stock. Reissued treasury stock will be accounted for at average cost. Gains or losses on reissued treasury stock arising from the difference between the average cost and the fair value of the award will be recorded in additional paid-in capital.

The Pacira BioSciences, Inc. Amended and Restated 2011 Stock Incentive Plan, or 2011 Plan, was originally adopted by its board of directors and approved by its stockholders in June 2011 and was amended and restated in June 2014, June 2016, June 2019, June 2021 and June 2023. The June 2023 amendment and restatement and approval by the Company’s stockholders increased the number of shares of common stock authorized for issuance as equity awards under the 2011 Plan by 3,300,000 shares, which allows for the granting of incentive stock options, non-statutory stock options, restricted stock units and other stock-based awards.

In April 2014, the Company’s board of directors approved and adopted the Company’s 2014 Inducement Plan (the “2014 Inducement Plan”), pursuant to which awards could be made to new employees under the 2014 Inducement Plan for up to 175,000 shares of the Company’s common stock as a material inducement to such persons entering into employment with the Company. In December 2023, the board of directors, upon recommendation of the people and compensation committee of the board of directors (the “P&C Committee”), adopted the Pacira BioSciences, Inc. Amended and Restated 2014 Inducement Plan (as amended and restated, the “First A&R Inducement Plan”) such that, among other things, an additional 642,093 shares of the Company’s common stock were reserved for issuance. In September 2024, the board of directors, upon the recommendation of the P&C Committee, adopted the Pacira BioSciences, Inc. Amended and Restated 2014 Inducement Plan (as amended and restated, the “Second A&R Inducement Plan”) to add an additional 707,907 shares of the Company’s common stock to bring the total amount of shares reserved for issuance under the Inducement Plan to 1,525,000. In January 2025, the board of directors, upon the recommendation of the P&C Committee, adopted the Pacira BioSciences, Inc. Amended and Restated 2014 Inducement Plan (as amended and restated to date, the “Inducement Plan”) to add an additional 785,000 shares of the Company’s common stock to bring the total amount of shares reserved for issuance under the Inducement Plan to 2,310,000, of which 465,007 shares remain available for issuance as of March 31, 2025, and extend the term of the Inducement Plan such that it will now expire on January 18, 2035.

The Inducement Plan allows for the granting of nonstatutory stock options, restricted stock awards and other stock-based awards, and was adopted by the board of directors without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market Listing Rules. In accordance with this rule, awards under the Inducement Plan may only be made to an employee who has not previously been an employee or member of the board of directors or the board of directors of any parent or subsidiary, or following a bona fide period of non-employment by the Company or a parent or subsidiary, if he or she is granted such award in connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary.

From time to time, the board of directors, upon recommendation of the P&C Committee, has approved individually negotiated grants of options and restricted stock units for certain of the Company’s officers in connection with their respective appointments, in each case, pursuant to the inducement plan in effect at such time.

The Company recognized stock-based compensation expense in the periods presented as follows (in thousands):

The following tables contain information about the Company’s stock option and restricted stock unit, or RSU, activity for the three months ended March 31, 2025: